Back to Search
Start Over
Oral baricitinib performs well in phase 3 study
- Source :
- Dermatology News. January, 2020, Vol. 51 Issue 1, p35, 1 p.
- Publication Year :
- 2020
-
Abstract
- MADRID -- Adding the oral Janus kinase (JAK) inhibitor baricitinib to standard atopic dermatitis (AD) therapy with low- and midpotency topical corticosteroids markedly improved disease severity and key patient-reported outcomes, [...]
Details
- Language :
- English
- ISSN :
- 23767006
- Volume :
- 51
- Issue :
- 1
- Database :
- Gale General OneFile
- Journal :
- Dermatology News
- Publication Type :
- Periodical
- Accession number :
- edsgcl.613203206